NewsRoom Articles - Page 112 of 154 - PsychedelicNewsWire (PNW)

WednesdayDec 16, 2020 12:42 pm

Traditional Chinese Medicine Takes Root in Western Culture with Rritual Superfoods Product Line

Rritual Superfoods, Inc., is a budding new superfood developer aiming to improve people’s overall wellness with purposefully designed elixirs pairing acclaimed mushroom varieties with adaptogenic herbs The company was organized earlier this year and has launched three initial product varieties using the Chaga, Reishi and Lion’s Mane mushrooms in tandem with adaptogenic roots plus herbal spices and natural whole foods Rritual’s products are designed to help users combat stress, strengthen their immune systems and enhance their mental clarity The nascent functional mushroom market is expected to grow with a CAGR of 8.04 percent between 2019 and 2024, according to Mordor…

TuesdayDec 15, 2020 3:15 pm

Could Prejudices Be Holding Us Back from Accepting Psychedelics as Mental Health Treatment?

Current pharmaceutical drugs for depression seem to be causing more harm than good to their users, with some patients developing a resistance to treatments while others become dependent on the treatments. This may be a reason for the increase in interest in the use of psychedelic drugs as alternative and potentially safer treatments for depression and other mental health conditions. The first time psychedelics were studied as a potential mental-health treatment was several decades ago, when researchers studied the therapeutic potential of LSD. However, as decades passed and various national and international drug policies were implemented, further research exploring the…

TuesdayDec 15, 2020 1:41 pm

Cybin Inc. (NEO: CYBN) on Right Path; Johns Hopkins Study Shows Psilocybin Positive Impact on Major Depression

Study published in “JAMA Psychiatry” reveals significant benefits of psilocybin for patients with major depression Most participants reported improvements; half experienced remission after only four weeks As an early entrant in the field, Cybin looks well placed to capitalize on growing traction that psychedelics gain as potential treatment of mental health conditions Only two doses of psilocybin accompanied with psychotherapy may lead to significant reductions in depressive symptoms in adults with major depression, according to recent research conducted by Johns Hopkins Medicine and published in “JAMA Psychiatry” (https://ibn.fm/AM1Ww). As a leading life sciences company focused on psychedelic drug development, Cybin…

MondayDec 14, 2020 12:00 pm

Tips to Becoming a Successful Psychedelic Retail Investor

The psychedelic medicine sector is booming and so is the interest in the market by investors. Pioneer clinical studies and research only help further this market along, bolstering its momentum. If you have an interest in investing in the market, here are a few things to take note of. Track projections and promises This may sound complicated, but it actually isn’t. Bonus: you don’t need training in finance to understand it. Tracking a firm’s profitability through its yearly projections is a simple way to find out whether a company’s results match its talk. Firms that fail to attain the targets…

FridayDec 11, 2020 3:00 pm

Psychedelics May Be the Next Big Investment Venture

The Controlled Substances Act was passed in the United States in the 1970s. The president at the time, Richard Nixon, approved the act as part of his war on drugs campaign. Under the act, cannabis was classified as a schedule 1 drug and was classified together with heroin and cocaine as extremely illegal and dangerous substances that were not allowed to be utilized in any medical applications. Currently, the legal cannabis market in the world is growing each year at an average of 40% and is valued at $17 billion. This is mainly attributed to the emerging research showing that…

ThursdayDec 10, 2020 1:45 pm

Billionaire Peter Thiel Invests in Psychedelic Drug Development

The mental health treatments being used around the world sometimes seem to be doing more harm than good to their consumers, with patients often becoming either addicted to their treatments or treatment resistant. Atai Life Sciences cofounder Florian Brand states that only 50% of individuals respond to selective serotonin reuptake inhibitors, which is the most common depression and anxiety treatment. In addition, this approach can take up to three months for an individual to notice any changes in their symptoms, and individuals have a 33% probability of their bodies resisting the treatment. Backed by its founders, Atai Life Sciences believes…

WednesdayDec 09, 2020 2:30 pm

Governor of Oregon Appoints Advisory Board to Begin Psilocybin Mushroom Therapy Regulation

In last month’s election, Oregon became the first U.S. state to legalize psychedelic mushroom use for various therapy purposes. Oregon Gov. Kate Brown is now implementing measures to kick off the program by accepting applications for board members. The board’s role will be to work out the process for regulating psychedelic treatment access. The Oregon Health Authority issued a notice last week that specified the criteria required for those who would like to apply for positions on the board. The board will consist of 14 to 16 members, and representatives of state departments such as the Department of Justice, public…

MondayDec 07, 2020 3:15 pm

Common Techniques Used in Psychedelic-Assisted Therapy

When discussing psychedelic therapy, many choose to focus on the experience the medication produces and neuropharmacology while ignoring therapy. However, we should acknowledge that without therapy, results from clinical trials wouldn’t be as comprehensive. Therapy plays a critical role in psychedelic therapy. Below, we discuss some of the common therapeutic approaches that psychedelic therapists use to help their patients heal. The Hakomi Technique This method was developed in the 1970s by Ron Kurtz. The technique helps patients focus on the experiences of the present, allowing them to understand the inner workings of their bodies. This method allows patients to restructure and…

MondayDec 07, 2020 2:47 pm

Rritual Superfoods Inc. Fields Powerhouse CPG Lineup to Market Functional Mushrooms

Demand for Functional Mushrooms Experiencing CAGR of Over 10 Percent Market Projected to Increase from $23 billion in 2020 to $34 billion by 2024 61% of the Americans Say Healthfulness Significantly Impacts Their Food Purchases Rritual Superfoods Offering Functional Products Based on Chaga, Lion’s Mane and Reishi Mushrooms Company Led by Stellar Consumer Packaged Goods (“CPG”) Executive Cast Functional foods are fast-rising fare for a growing number of Americans. It’s the same on the world stage, where similar forces are in play. As a result, the functional foods market is projected to continue its current 7.9% CAGR until the year…

FridayDec 04, 2020 12:15 pm

Psychedelics, Kids and Culture

Children and drugs should not mix — unless, of course, the drugs are prescribed by a doctor. However, as the medicalization, decriminalization and legalization of various substances increases or expands, many believe it may be time to have that conversation with their children because drugs are only becoming more accessible as time passes. While you may not expose your children to recreational drugs of any kind, not everyone else may be as quick to say no. In fact, children are often surrounded by information about and access to a variety of drugs. Here is some valuable information about psychedelic substances…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000